Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparison of Two Insulin Detemir Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin detemir

First Posted Date: 2011-12-26

Last Posted Date: 2015-01-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT01498926

Within-subject Variability of Insulin Detemir in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin glargine
Drug: insulin detemir

First Posted Date: 2011-12-22

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01497535

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: insulin detemir

First Posted Date: 2011-12-22

Last Posted Date: 2017-01-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 20

Registration Number: NCT01497587

Locations: 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan

Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin NPH
Drug: insulin detemir

First Posted Date: 2011-12-22

Last Posted Date: 2017-01-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT01497561

Locations: 🇩🇪
Novo Nordisk Investigational Site, Graz, Germany

Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin detemir
Drug: insulin glargine

First Posted Date: 2011-12-22

Last Posted Date: 2017-01-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01497574

Locations: 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin detemir
Drug: insulin NPH

First Posted Date: 2011-12-22

Last Posted Date: 2017-01-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 50

Registration Number: NCT01497600

Locations: 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

Phase 3

Completed

Conditions: Haemophilia A
Congenital Bleeding Disorder

Interventions: Drug: turoctocog alfa

First Posted Date: 2011-12-16

Last Posted Date: 2020-11-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT01493778

Locations: 🇹🇷
Novo Nordisk Investigational Site, Samsun, Turkey

To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin

First Posted Date: 2011-12-16

Last Posted Date: 2017-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 402

Registration Number: NCT01493388

Locations: 🇹🇳
Novo Nordisk Investigational Site, Tunisia, Tunisia

Observational Study With InnoLet® in Daily Clinical Practice

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin human

First Posted Date: 2011-12-15

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1030

Registration Number: NCT01492959

Locations: 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of

Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic human insulin 30

First Posted Date: 2011-12-14

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1330

Registration Number: NCT01492218

Locations: 🇵🇭
Novo Nordisk Investigational Site, Manilla, Philippines

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy